Bicycle Therapeutics (BCYC) Competitors $8.00 -0.09 (-1.11%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$7.50 -0.51 (-6.31%) As of 07/11/2025 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC vs. CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, HRMY, ADPT, and SRPTShould you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Harmony Biosciences (HRMY), Adaptive Biotechnologies (ADPT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Bicycle Therapeutics vs. Its Competitors CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Adaptive Biotechnologies Sarepta Therapeutics CG Oncology (NASDAQ:CGON) and Bicycle Therapeutics (NASDAQ:BCYC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Do analysts recommend CGON or BCYC? CG Oncology currently has a consensus target price of $56.80, suggesting a potential upside of 112.57%. Bicycle Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 212.50%. Given Bicycle Therapeutics' higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08Bicycle Therapeutics 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.70 Is CGON or BCYC more profitable? Bicycle Therapeutics has a net margin of -790.07% compared to CG Oncology's net margin of -15,945.17%. CG Oncology's return on equity of -16.71% beat Bicycle Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-15,945.17% -16.71% -16.24% Bicycle Therapeutics -790.07%-25.54%-21.23% Do institutionals & insiders hold more shares of CGON or BCYC? 26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 7.4% of CG Oncology shares are owned by insiders. Comparatively, 22.9% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, CGON or BCYC? CG Oncology has higher earnings, but lower revenue than Bicycle Therapeutics. CG Oncology is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$1.14M1,786.49-$88.04M-$1.51-17.70Bicycle Therapeutics$35.28M15.70-$169.03M-$3.14-2.55 Does the media favor CGON or BCYC? In the previous week, Bicycle Therapeutics had 9 more articles in the media than CG Oncology. MarketBeat recorded 12 mentions for Bicycle Therapeutics and 3 mentions for CG Oncology. CG Oncology's average media sentiment score of 1.49 beat Bicycle Therapeutics' score of 0.16 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, CGON or BCYC? CG Oncology has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. SummaryCG Oncology beats Bicycle Therapeutics on 9 of the 17 factors compared between the two stocks. Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCYC vs. The Competition Export to ExcelMetricBicycle TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$560.26M$2.99B$5.61B$9.11BDividend YieldN/A2.39%5.24%4.02%P/E Ratio-2.5520.5827.9620.25Price / Sales15.70292.00430.8999.65Price / CashN/A42.8637.4658.16Price / Book0.707.638.045.49Net Income-$169.03M-$55.05M$3.18B$250.27M7 Day Performance7.74%8.54%3.67%4.80%1 Month Performance-7.94%5.51%4.09%7.68%1 Year Performance-64.70%2.03%29.58%16.36% Bicycle Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCYCBicycle Therapeutics3.7292 of 5 stars$8.00-1.1%$25.00+212.5%-64.0%$560.26M$35.28M-2.55240News CoverageCGONCG Oncology2.4167 of 5 stars$26.25-2.4%$58.67+123.5%-22.5%$2.05B$1.14M-17.3861Positive NewsAnalyst UpgradeKNSAKiniksa Pharmaceuticals International3.5322 of 5 stars$27.95+0.3%$38.80+38.8%+30.0%$2.03B$423.24M-111.80220Positive NewsAnalyst ForecastBEAMBeam Therapeutics2.1252 of 5 stars$19.18-4.1%$48.75+154.2%-18.2%$2.01B$63.52M-4.16510IDYAIDEAYA Biosciences3.613 of 5 stars$21.16-4.3%$53.42+152.4%-43.3%$1.94B$7M-5.8980News CoverageAnalyst UpgradeIRONDisc Medicine3.2092 of 5 stars$53.38-2.5%$96.70+81.2%+21.3%$1.90BN/A-13.6230Insider TradeBLTEBelite Bio2.3587 of 5 stars$58.63-1.4%$96.67+64.9%+29.2%$1.89BN/A-43.1110News CoverageAnalyst RevisionCNTACentessa Pharmaceuticals3.2499 of 5 stars$13.62-3.2%$27.89+104.8%+50.8%$1.88B$6.85M-7.52200HRMYHarmony Biosciences4.8611 of 5 stars$32.24+0.2%$53.63+66.3%+2.0%$1.85B$714.73M12.31200News CoveragePositive NewsAnalyst ForecastADPTAdaptive Biotechnologies2.8522 of 5 stars$11.74-0.5%$10.57-10.0%+203.9%$1.79B$178.96M-12.23790SRPTSarepta Therapeutics4.7103 of 5 stars$17.32-5.0%$60.88+251.5%-88.1%$1.79B$1.90B-6.441,372Trending NewsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies CG Oncology Competitors Kiniksa Pharmaceuticals International Competitors Beam Therapeutics Competitors IDEAYA Biosciences Competitors Disc Medicine Competitors Belite Bio Competitors Centessa Pharmaceuticals Competitors Harmony Biosciences Competitors Adaptive Biotechnologies Competitors Sarepta Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCYC) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCYC Stock Alerts